
He describes the darovasertib filing, which IDEAYA hopes will be for all metastatic uveal melanoma patients. Plus, what makes DLL3 a compelling target, and how interest in PRMT5 has especially taken off given how prevalent MTAP deletions are in pancreatic cancer.
Nov 18
11 min

Co-Owner and Managing Partner Sander Slootweg discusses the new funds and what kind of companies the funds might be deployed towards. He also shares his ideas and recommendations on how to make Europe more competitive in life sciences and keep companies in the region, and gives his take on the sector's outlook in 2027.
Nov 18
12 min

CEO Jason Coloma describes the unmet need in this area - which affects younger people compared to most other chronic kidney conditions. He walks us through MZE829, which just completed enrollment the phase 2 HORIZON trial and will have data in early 2027.
Nov 18
13 min

President and CEO Andrew Hirsch describes the concept of protein degraders in general, and the paper that sparked the creation of C4 as a company. He discusses the company's registration intended trial, and another one in combination with a T-cell engager from Pfizer.
Nov 18
12 min

He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
Nov 18
14 min

CEO Jonathan Lim descrbies the profile of ERAS-0015 and the data the company has derived up to this point. A phase 3 study is planned in 1st line pancreatic cancer in the early part of 2027 and two in lung later in the year. He also discusses combinations, including with Erasca's own KRAS inhibitor.
Nov 18
13 min

CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
Nov 18
11 min

The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
Nov 17
9 min

They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.
Nov 17
19 min

He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for.
Nov 17
14 min
Load more
